Anti-EIF3A antibodies were detected in patients’ sera at all tumor stages (TNM stage I to IV) and sizes, even at initial tumor stages (TNM stage I) or in tumor burden of small sizes (T < 2). Here, EIF3A is linked to neoplasm.